چكيده لاتين :
Research on non-hemodialysis patients has shown that u)3-fatty acid supplement can reduce the concentration of serum Lp(a). Therefore, the present study was designed to investigate the effects of u)3-fatty acid supplement on serum lipids and lipoproteins in hemodialysis patients. Methods and Materials: This double-blind randomized clinical trial was conducted on 40 hemodialysis patients in 2008 in Vaseʹi Hospital in Sabzevar, Iran; they were randomly assigned to either co3-fatty acid supplement or placebo group. Patients in the u)3-fatty acid supplement group received 2080 mg u>3-fatty acid daily as 4 capsules, while the placebo group received 4 corresponding placebo capsules containing MCT oil. At baseline and the end of week 10 of the study, 5 ml blood samples were collected from each patient after a 12 to 14-hour fasting before dialysis; their serum triglyceride, total cholesterol, LDL-C, HDL-C and Lp(a) were measured. The obtained data were analyzed in SPSS using Chi-square, t-test, paired t-test and ANOVA. Results: Serum triglyceride concentration were 113±32 and 109±19 in the supplement and placebo groups respectively in the beginning; the amounts decreased to 101 ±25 and 115±17 at the end of week 10. The reduction was significant in the supplement group (p<0.01) and the difference between the supplement and placebo group was significant (P<0.0.006). However, no significant differences were observed between the two groups as for the changes of serum total cholesterol, LDL-C, HDL-C and Lp(a) concentrations (P>0.05).
Conclusion: Results of the present study indicate that ca3-fatty acid supplement can reduce serum triglyceride concentration in hemodialysis patients but it does not affect other serum lipids and lipoproteins in hemodialysis patients. (Journal of Sabzevar University of Medical Sciences, Volume 16, Number I, pp.25-34).
